Published in CMAJ on July 22, 2003
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Canadian study of health and aging: study methods and prevalence of dementia. CMAJ (1994) 6.91
Risks and benefits of hormone replacement therapy: the evidence speaks. CMAJ (2003) 1.63
Hormone replacement therapy: a time for pause. CMAJ (2002) 1.52
Tips for learning and teaching evidence-based medicine: introduction to the series. CMAJ (2004) 3.23
Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ (2002) 2.41
Herbal kava: reports of liver toxicity. CMAJ (2002) 2.17
Concerns over lindane treatment for scabies and lice. CMAJ (2003) 2.01
Droperidol: cardiovascular toxicity and deaths. CMAJ (2002) 1.68
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ (2002) 1.64
Cochlear implant recipients at risk for meningitis. CMAJ (2002) 1.61
Rosiglitazone (Avandia) and macular edema. CMAJ (2006) 1.50
A catalyst for change. CMAJ (2006) 1.48
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ (2004) 1.43
Alcohol-associated rapid release of a long-acting opioid. CMAJ (2005) 1.42
Congratulations to our colleagues at Open Medicine. CMAJ (2007) 1.39
Brief safety updates: acetaminophen, ASA and kava. CMAJ (2002) 1.38
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ (2005) 1.29
Too much of a good thing? Toxic effects of vitamin and mineral supplements. CMAJ (2003) 1.27
Propofol: contraindicated for sedation of pediatric intensive care patients. CMAJ (2002) 1.25
Diane-35 (cyproterone acetate): safety concerns. CMAJ (2003) 1.22
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ (2002) 1.18
Paroxetine (Paxil) and congenital malformations. CMAJ (2005) 1.03
Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. CMAJ (2002) 0.99
Salmeterol (Serevent) asthma trial halted early. CMAJ (2003) 0.99
Rosuvastatin (Crestor) and rhabdomyolysis. CMAJ (2004) 0.97
Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ (2005) 0.94
Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ (2005) 0.93
Tamoxifen for breast cancer prevention: safety warning. CMAJ (2002) 0.92
Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ (2002) 0.90
Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ (2002) 0.90
Facts on mercury and fish consumption. CMAJ (2002) 0.88
Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients. CMAJ (2003) 0.88
Visual loss with erectile dysfunction medications. CMAJ (2006) 0.88
Ephedra/ephedrine: cardiovascular and CNS effects. CMAJ (2002) 0.88
HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome. CMAJ (2002) 0.87
Noninvasive treatments for umbilical granulomas. Am Fam Physician (2003) 0.85
Long-acting beta2-agonists in asthma: safety concerns. CMAJ (2005) 0.84
Accutane (isotretinoin) and psychiatric adverse effects. CMAJ (2003) 0.83
Suicidal ideation among children taking atomoxetine (Strattera). CMAJ (2005) 0.83
Failure of rapid HIV tests. CMAJ (2002) 0.83
Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ (2007) 0.83
People with diabetes should avoid antibiotic gatifloxacin. CMAJ (2006) 0.82
Septic shock after medical abortions with mifepristone (Mifeprex, RU 486) and misoprostol. CMAJ (2005) 0.82
The Canadian Hypertension Education Program (CHEP) recommendations: launching a new series. CMAJ (2005) 0.82
Striving for excellence: developing a framework for the Triple C curriculum in family medicine education. Can Fam Physician (2012) 0.82
Infliximab and serious hematologic events. CMAJ (2004) 0.80
Medications for attention deficit hyperactivity disorder: cardiovascular concerns. CMAJ (2006) 0.80
Mefloquine: contraindicated in patients with mood, psychotic or seizure disorders. CMAJ (2002) 0.79
Asthma drug zafirlukast (Accolate): serious hepatic events. CMAJ (2004) 0.79
Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. CMAJ (2005) 0.79
Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss. CMAJ (2005) 0.78
Oseltamivir (Tamiflu) unsafe in infants under 1 year old. CMAJ (2004) 0.78
HIV drug nevirapine (Viramune): risk of severe hepatotoxicity. CMAJ (2004) 0.78
Nephrology in practice: a new series. CMAJ (2002) 0.77
Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia. CMAJ (2004) 0.76
Osteoporosis treatment: raloxifene (Evista) and stroke mortality. CMAJ (2006) 0.76
Triptan migraine treatments and antidepressants: risk of serotonin syndrome. CMAJ (2006) 0.75
Meniscus. CMAJ (2002) 0.75
WinRho and disseminated intravascular coagulopathy. CMAJ (2006) 0.75
Ototoxic effects from gentamicin ear drops. CMAJ (2002) 0.75
Persistent pulmonary hypertension of the newborn and maternal use of SSRIs. CMAJ (2006) 0.75
Nail gun. CMAJ (2002) 0.75
Is the timing of infant cereal introduction a risk factor for celiac disease autoimmunity? CMAJ (2005) 0.75
Hua Fo tablets tainted with sildenafil-like compound. CMAJ (2002) 0.75
The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns. CMAJ (2005) 0.75
Several Chinese herbal products may contain toxic aristolochic acid. CMAJ (2004) 0.75
Serious allergic reactions following tuberculin skin tests. CMAJ (2005) 0.75
Medical gels and the risk of serious infection. CMAJ (2004) 0.75
Earlier clinical conundrum resolved: a diagnosis with teeth. CMAJ (2005) 0.75
Epoetin alfa (Eprex): reports of pure red blood cell aplasia. CMAJ (2002) 0.75
Patient information about HPV and the HPV vaccine. CMAJ (2007) 0.75